|
 |
 |  |
New Safety Concerns for Antipsychotic Treatments
In the December 1, 2009, issue of Biological Psychiatry, a multi-university research
group led by Dr. Jonathan Meyer at the Department of Psychiatry, University of California
at San Diego, discussed a cluster of metabolic side effects associated with a number
of antipsychotic medications. The results illustrate a growing concern with antipsychotic
medications due to a higher cardiovascular mortality among the severely mentally
ill compared to the general population. Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects
in Phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness Study
The cluster of metabolic side effects associated with a number of antipsychotic
medications includes weight gain, hyperglycemia, and hyperlipidemia. In their paper,
the research group presented data on how these metabolic side effects may contribute
to the risk for diabetes, hypertension, and other medical disorders associated with
heart disease.
The group’s study focused on the effects of antipsychotics on inflammatory markers
in the blood and the markers’ role as important indicators of cardiovascular risk.
Their research examined the impact of multiple antipsychotic therapies on changes
in systemic inflammation. The findings provide evidence that antipsychotic medications—particularly
olanzapine (Zyprexa®) and quetiapine (Seroquel®)—increase the levels of inflammation
markers. The specific inflammation markers examined in the study are associated
with an increased risk for the development or progression of many illnesses including
heart disease and stroke.
Dr. Meyer noted that these results provide compelling evidence to date for the association
between antipsychotic treatment and changes in the markers of systemic inflammation.
He believes this work supports the need for monitoring cardiovascular risk markers
in patients who are treated with antipsychotics.
Cerilliant offers certified reference standards of atypical antipsychotics including
clozapine,
risperidone, olanzapine,
and
quetiapine as well as typical antipsychotics such as
chlorpromazine, haloperidol,
thioridazine, and
fluphenazine. Cerilliant’s certified solution standards offer significant
benefits to the laboratory such as increased efficiency, convenience of use with
Snap-N-Shoot® or Snap-N-SpikeTM capability, and retest/expiration
dates supported by real time stability data. Click on the link below to view our
comprehensive list of antipsychotic standards:
Cerilliant Certified Reference Standards of Antipsychotic Drugs
Return to Article List
|
|
|
|